OM
RGLS

Opaleye Management’s Regulus Therapeutics RGLS Stock Holding History

Opaleye Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-535,000
Closed -$840K – 47
2024
Q3 		$840K Sell
535,000
-940,000
-64% -$1.56M 0.14% 42
2024
Q2 		$2.63M Buy
1,475,000
+1,304,692
+766% +$3.03M 0.6% 40
2024
Q1 		$490K Buy
+170,308
New +$278K 0.11% 50

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management's RGLS Position: Q4 2024 in Review

Opaleye Management sold out of Regulus Therapeutics (RGLS) in Q4 2024, closing a stake of 535,000 shares — an estimated $840K sold.

Opaleye Management first reported a position in RGLS in Q1 2024 and held it in 3 quarters. The position peaked at $2.63M in Q2 2024. 69 funds tracked by Wall St. Rank hold RGLS as of Q4 2024.

  • Opaleye Management reported no remaining Regulus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Opaleye Management sold 535,000 Regulus Therapeutics shares in Q4 2024, an estimated $840K.
  • Opaleye Management first reported a position in Regulus Therapeutics in Q1 2024 and held it in 3 quarters.
  • Opaleye Management's Regulus Therapeutics position peaked at $2.63M in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2024.

Based on Opaleye Management's 13F filing for Q4 2024, filed 14 Feb 2025.